ARS Pharmaceuticals(US:SPRY) Globenewswire·2024-12-13 21:58Core Insights - ARS Pharmaceuticals, Inc. has announced the launch of neffy®, a nasal spray formulation for the treatment of allergic reactions, which is now available in the United States [1][4] - The product is designed to be administered quickly and effectively, with a recommended dosage of 2 milligrams for individuals weighing 30 kg (66 pounds) or more [1][2] - The company aims to expand its market presence in Europe, with plans to introduce neffy® in the European market by August 2024 [1][4] Product Details - Neffy® is a nasal spray that provides a rapid response for treating allergic reactions, specifically designed for individuals aged 6 to 17 years [1][2] - Clinical studies have shown that neffy® is effective in treating severe allergic reactions, achieving a 100% response rate in certain trials [1][3] - The product can be stored at temperatures up to 122°F (50°C) and is designed for ease of use [1][2] Market Strategy - ARS Pharmaceuticals is collaborating with various partners, including Pediatrix Therapeutics and CSL Seqirus, to enhance distribution and market reach [1][4] - The company is focused on increasing awareness and accessibility of neffy® among healthcare providers and patients [1][3] - Future plans include further clinical research and potential expansion into additional markets beyond the U.S. and Europe [1][4]